Name: Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2030
Brand: MarketsandMarkets
SKU: PH9204
Price: 4950 USD
Availability: InStock

1 INTRODUCTION 32 1.1 STUDY OBJECTIVES 32 1.2 MARKET DEFINITION 32 1.3 MARKET SCOPE 33 1.3.1 MARKETS AND REGIONS COVERED 33 1.3.2 INCLUSIONS & EXCLUSIONS 34 1.3.3 YEARS CONSIDERED 34 1.3.4 CURRENCY CONSIDERED 35 1.4 STAKEHOLDERS 35 1.5 SUMMARY OF CHANGES 35 2 RESEARCH METHODOLOGY 36 2.1 RESEARCH DATA 36 2.1.1 RESEARCH DESIGN 36 2.1.2 SECONDARY DATA 37 2.1.3 PRIMARY DATA 37 2.2 MARKET SIZE ESTIMATION 39 2.2.1 INSIGHTS FROM PRIMARIES 41 2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL 41 2.3 MARKET GROWTH FORECAST 42 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 44 2.5 STUDY ASSUMPTIONS 45 2.6 RESEARCH LIMITATIONS 45 2.7 RISK ANALYSIS 45 3 EXECUTIVE SUMMARY 46 4 PREMIUM INSIGHTS 50 4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW 50 4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2024) 51 4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2024 51 4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2025 VS. 2030 52 4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52 5 MARKET OVERVIEW 53 5.1 INTRODUCTION 53 5.2 MARKET DYNAMICS 53 5.2.1 DRIVERS 54 5.2.1.1 Increasing burden of chronic diseases 54 5.2.1.2 Advancements in drug delivery technologies 55 5.2.1.3 Higher patient compliance and preference for oral route 55 5.2.1.4 Expanding therapeutic applications of oral proteins & peptides 55 5.2.2 RESTRAINTS 56 5.2.2.1 High cost of drug development 56 5.2.2.2 Contraindication of oral proteins & peptides 56 5.2.2.3 Stringent regulatory approval process 56 5.2.3 OPPORTUNITIES 57 5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides 57 5.2.3.2 Growing demand for personalized medicine 57 5.2.4 CHALLENGES 58 5.2.4.1 Hurdles in formulation and stability 58 5.2.4.2 Availability of alternative therapies 58 5.3 ECOSYSTEM ANALYSIS 59 5.3.1 ROLE OF RAW MATERIAL VENDORS 60 5.3.2 ROLE OF PRODUCT PROVIDERS 60 5.3.3 ROLE OF END USERS 60 5.3.4 ROLE OF REGULATORY AUTHORITIES 61 5.4 VALUE CHAIN ANALYSIS 61 5.5 SUPPLY CHAIN ANALYSIS 63 5.6 PORTER’S FIVE FORCES ANALYSIS 64 5.6.1 THREAT OF NEW ENTRANTS 65 5.6.2 THREAT OF SUBSTITUTES 65 5.6.3 BARGAINING POWER OF SUPPLIERS 66 5.6.4 BARGAINING POWER OF BUYERS 66 5.6.5 INTENSITY OF COMPETITIVE RIVALRY 66 5.7 KEY STAKEHOLDERS & BUYING CRITERIA 66 5.7.1 KEY STAKEHOLDERS 66 5.7.2 BUYING CRITERIA 67 5.8 PRICING ANALYSIS 69 5.8.1 AVERAGE SELLING PRICE, BY KEY PLAYER 69 5.8.2 AVERAGE SELLING PRICE, BY COUNTRY & REGION 70 5.9 REGULATORY LANDSCAPE 71 5.9.1 REGULATORY SCENARIO 71 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75 5.11 TECHNOLOGY ANALYSIS 75 5.11.1 KEY TECHNOLOGIES 75 5.11.1.1 Transient permeation enhancers 75 5.11.1.2 Gastrointestinal permeation enhancement technology 75 5.11.1.3 Oral sCT (OSTORA) technology 76 5.11.2 COMPLEMENTARY TECHNOLOGIES 76 5.11.2.1 Peptelligence 76 5.11.2.2 ThioMatrix 76 5.11.2.3 Transferrin-based recombinant fusion proteins 77 5.11.3 ADJACENT TECHNOLOGIES 77 5.11.3.1 Oramed and Orasome 77 5.11.3.2 Q-sphera 77 5.11.3.3 Nanoinclusion 77 5.11.3.4 Oleotec and Soctec 78 5.12 PIPELINE ANALYSIS 78 5.13 PATENT ANALYSIS 79 5.13.1 METHODOLOGY 79 5.13.2 PATENTS APPLIED AND GRANTED, 2014–2025 79 5.14 REIMBURSEMENT SCENARIO 82 5.15 KEY CONFERENCES & EVENTS, 2025–2026 82 5.16 INVESTMENT & FUNDING SCENARIO 83 5.17 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET 85 5.18 IMPACT OF 2025 US TARIFFS—ORAL PROTEINS & PEPTIDES MARKET 86 5.18.1 INTRODUCTION 86 5.18.2 KEY TARIFF RATES 86 5.18.3 PRICE IMPACT ANALYSIS 87 5.18.4 IMPACT ON COUNTRIES/REGIONS 87 5.18.4.1 US 87 5.18.4.2 Europe 87 5.18.4.3 Asia Pacific 88 5.18.5 IMPACT ON MANUFACTURING INDUSTRIES 88 5.18.6 RECOMMENDATIONS FOR MANUFACTURERS 88 6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE 90 6.1 INTRODUCTION 91 6.2 SEMAGLUTIDE 91 6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH 91 6.3 CALCITONIN 94 6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION 94 6.4 LINACLOTIDE 97 6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH 97 6.5 TROFINETIDE 99 6.5.1 FDA APPROVAL TO DRIVE MARKET 99 6.6 VOCLOSPORIN 102 6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION 102 6.7 PLECANATIDE 104 6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH 104 6.8 OTHER MOLECULES 107 7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS 110 7.1 INTRODUCTION 111 7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS 111 7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH 111 7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS 114 7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION 114 7.4 GUANYLATE CYCLASE-C AGONISTS 117 7.4.1 RISING PREVALENCE OF IBS AND CIC TO DRIVE MARKET 117 7.5 GLYCINE-PROLINE-GLUTAMATE 119 7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH 119 7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS 122 7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH 122 7.7 OTHER DRUG CLASSES 124 8 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION 127 8.1 INTRODUCTION 128 8.2 TABLETS 128 8.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH 128 8.3 CAPSULES 131 8.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET 131 8.4 ORAL SOLUTIONS 134 8.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH 134 9 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA 137 9.1 INTRODUCTION 138 9.2 DIABETES 138 9.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION 138 9.3 CNS DISORDERS 142 9.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET 142 9.4 GASTROENTEROLOGY 145 9.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH 145 9.5 GENETIC DISORDERS 148 9.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH 148 9.6 NEPHROLOGY 151 9.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET 151 9.7 OBESITY & OVERWEIGHT 153 9.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH 153 9.8 OTHER THERAPEUTIC AREAS 156 10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER 159 10.1 INTRODUCTION 160 10.2 HOME CARE SETTINGS 160 10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH 160 10.3 LONG-TERM CARE FACILITIES 163 10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH 163 10.4 HOSPITALS & SPECIALTY CLINICS 166 10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO DRIVE MARKET 166 11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION 170 11.1 INTRODUCTION 171 11.2 NORTH AMERICA 171 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 172 11.2.2 US 176 11.2.2.1 US to hold large shares in North American and global markets 176 11.2.3 CANADA 178 11.2.3.1 Increasing prevalence of obesity and heart failure to support market growth 178 11.3 EUROPE 180 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 181 11.3.2 GERMANY 185 11.3.2.1 Germany to hold largest share of European market 185 11.3.3 UK 188 11.3.3.1 Strong focus on advancement of life sciences to support market growth 188 11.3.4 FRANCE 190 11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth 190 11.3.5 ITALY 193 11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market 193 11.3.6 SPAIN 195 11.3.6.1 Initiatives associated with GLP-1 drugs to drive market 195 11.3.7 NETHERLANDS 198 11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth 198 11.3.8 REST OF EUROPE 200 11.4 ASIA PACIFIC 202 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 203 11.4.2 CHINA 207 11.4.2.1 Increasing R&D expenditure to drive market 207 11.4.3 JAPAN 209 11.4.3.1 Increasing prevalence of diabetes to drive market 209 11.4.4 INDIA 212 11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth 212 11.4.5 AUSTRALIA 214 11.4.5.1 Rising access to GLP-1 drugs and government support to drive market 214 11.4.6 SOUTH KOREA 217 11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth 217 11.4.7 REST OF ASIA PACIFIC 219 11.5 LATIN AMERICA 222 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 222 11.5.2 BRAZIL 225 11.5.2.1 Brazil to hold largest market share in Latin America 225 11.5.3 MEXICO 228 11.5.3.1 Growing diabetes and obesity cases to drive market 228 11.5.4 REST OF LATIN AMERICA 230 11.6 MIDDLE EAST 233 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 233 11.6.2 GCC COUNTRIES 236 11.6.2.1 Saudi Arabia 239 11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth 239 11.6.2.2 UAE 241 11.6.2.2.1 Regulatory approvals for GLP-1 drugs to propel market 241 11.6.2.3 Rest of GCC countries 244 11.6.3 REST OF MIDDLE EAST 246 11.7 AFRICA 248 11.7.1 LARGE AND GROWING PATIENT POPULATION AND FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET 248 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 248 12 COMPETITIVE LANDSCAPE 252 12.1 OVERVIEW 252 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 252 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET 252 12.3 REVENUE ANALYSIS, 2022–2024 253 12.4 MARKET SHARE ANALYSIS, 2024 254 12.5 COMPANY EVALUATION MATRIX 256 12.5.1 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 256 12.5.1.1 Stars 256 12.5.1.2 Emerging leaders 256 12.5.1.3 Pervasive players 257 12.5.1.4 Participants 257 12.5.2 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2024 258 12.5.2.1 Stars 258 12.5.2.2 Emerging leaders 258 12.5.2.3 Pervasive players 258 12.5.2.4 Participants 258 12.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2024 260 12.5.3.1 Company footprint 260 12.5.3.2 Region footprint 262 12.5.3.3 Molecule footprint 263 12.5.3.4 Formulation footprint 264 12.5.3.5 Therapeutic area footprint 264 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 266 12.6.1 PROGRESSIVE COMPANIES 266 12.6.2 RESPONSIVE COMPANIES 266 12.6.3 DYNAMIC COMPANIES 266 12.6.4 STARTING BLOCKS 266 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 268 12.6.5.1 Detailed list of key startups/SMEs 268 12.6.5.2 Competitive benchmarking of key startups/SMEs 269 12.7 VALUATION & FINANCIAL METRICS 270 12.7.1 FINANCIAL METRICS 270 12.7.2 COMPANY VALUATION 270 12.8 BRAND/PRODUCT COMPARISON 271 12.9 COMPETITIVE SCENARIO 271 12.9.1 PRODUCT APPROVALS 271 12.9.2 DEALS 273 12.9.3 EXPANSIONS 274 12.9.4 OTHER DEVELOPMENTS 275 13 COMPANY PROFILES 276 13.1 INTRODUCTION 276 13.2 KEY PLAYERS 276 13.2.1 NOVO NORDISK A/S 276 13.2.1.1 Business overview 276 13.2.1.2 Products offered 277 13.2.1.3 Recent developments 278 13.2.1.3.1 Product launches & approvals 278 13.2.1.3.2 Deals 278 13.2.1.3.3 Expansions 279 13.2.1.3.4 Other developments 280 13.2.1.4 MnM view 280 13.2.1.4.1 Right to win 280 13.2.1.4.2 Strategic choices 280 13.2.1.4.3 Weaknesses & competitive threats 280 13.2.2 ABBVIE INC. 281 13.2.2.1 Business overview 281 13.2.2.2 Products offered 282 13.2.2.3 Recent developments 283 13.2.2.3.1 Product approvals 283 13.2.2.3.2 Deals 283 13.2.2.4 MnM view 284 13.2.2.4.1 Right to win 284 13.2.2.4.2 Strategic choices 284 13.2.2.4.3 Weaknesses & competitive threats 284 13.2.3 PFIZER INC. 285 13.2.3.1 Business overview 285 13.2.3.2 Product pipeline 286 13.2.3.3 Recent developments 287 13.2.3.3.1 Product approvals 287 13.2.3.3.2 Deals 287 13.2.3.3.3 Other developments 287 13.2.3.4 MnM view 288 13.2.3.4.1 Right to win 288 13.2.3.4.2 Strategic choices 288 13.2.3.4.3 Weaknesses & competitive threats 288 13.2.4 BAUSCH HEALTH COMPANIES INC. 289 13.2.4.1 Business overview 289 13.2.4.2 Products offered 290 13.2.4.3 Recent developments 291 13.2.4.3.1 Product approvals 291 13.2.5 CHIESI FARMACEUTICI S.P.A. 292 13.2.5.1 Business overview 292 13.2.5.2 Products offered 293 13.2.5.3 Recent developments 294 13.2.5.3.1 Deals 294 13.2.6 ACADIA PHARMACEUTICALS INC. 295 13.2.6.1 Business overview 295 13.2.6.2 Products offered 296 13.2.6.3 Recent developments 296 13.2.6.3.1 Product approvals 296 13.2.7 AURINIA PHARMACEUTICALS INC. 297 13.2.7.1 Business overview 297 13.2.7.2 Products offered 298 13.2.7.3 Recent developments 298 13.2.7.3.1 Product approvals 298 13.2.8 MERCK & CO., INC. 300 13.2.8.1 Business overview 300 13.2.8.2 Product pipeline 301 13.2.8.3 Recent developments 302 13.2.8.3.1 Deals 302 13.2.8.3.2 Other developments 302 13.2.9 JOHNSON & JOHNSON SERVICES, INC. 303 13.2.9.1 Business overview 303 13.2.9.2 Product pipeline 304 13.2.9.3 Recent developments 305 13.2.9.3.1 Other developments 305 13.2.10 SWK HOLDINGS 306 13.2.10.1 Business overview 306 13.2.10.2 Product pipeline 307 13.2.10.3 Recent developments 307 13.2.10.3.1 Other developments 307 13.2.11 R-PHARM JSC 308 13.2.11.1 Business overview 308 13.2.11.2 Products in pipeline 308 13.2.12 ENTERA BIO LTD. 309 13.2.12.1 Business overview 309 13.2.12.2 Product pipeline 309 13.2.12.3 Recent developments 310 13.2.12.3.1 Deals 310 13.2.12.3.2 Other developments 310 13.2.13 PROXIMA CONCEPTS 311 13.2.13.1 Business overview 311 13.2.13.2 Products in pipeline 311 13.3 OTHER PLAYERS 312 13.3.1 ASTRAZENECA PLC 312 13.3.2 REGOR THERAPEUTICS GROUP 312 13.3.3 TERNS PHARMACEUTICALS, INC. 313 13.3.4 STRUCTURE THERAPEUTICS 313 13.3.5 VIKING THERAPEUTICS 314 13.3.6 PROTAGONIST THERAPEUTICS INC. 314 13.3.7 RANI THERAPEUTICS 315 13.3.8 CARMOT THERAPEUTICS, INC. 315 13.3.9 ZEALAND PHARMA 316 13.3.10 SCIWIND BIOSCIENCES CO., LTD. 316 13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 317 14 APPENDIX 318 14.1 DISCUSSION GUIDE 318 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 322 14.3 CUSTOMIZATION OPTIONS 324 14.4 RELATED REPORTS 324 14.5 AUTHOR DETAILS 325

TABLE 1 ORAL PROTEINS & PEPTIDES MARKET: IMPACT ANALYSIS 54 TABLE 2 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF RAW MATERIAL VENDORS 60 TABLE 3 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF PRODUCT PROVIDERS 60 TABLE 4 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF END USERS 60 TABLE 5 ORAL PROTEINS & PEPTIDES MARKET: ROLE OF REGULATORY AUTHORITIES 61 TABLE 6 ORAL PROTEINS & PEPTIDES MARKET: PORTER’S FIVE FORCES ANALYSIS 64 TABLE 7 BUYING CRITERIA FOR ORAL PROTEINS & PEPTIDES, BY END USER 68 TABLE 8 AVERAGE SELLING PRICE OF ORAL PROTEIN & PEPTIDE PRODUCTS, BY KEY PLAYER, 2024 (USD) 69 TABLE 9 AVERAGE SELLING PRICE OF ORAL PROTEIN & PEPTIDE PRODUCTS, BY COUNTRY AND REGION, 2024 (USD) 70 TABLE 10 REGULATORY SCENARIO FOR ORAL PROTEINS & PEPTIDES MARKET 71 TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73 TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 15 ORAL PEPTIDES IN CLINICAL PIPELINE (AS OF JANUARY 2025) 78 TABLE 16 PATENTS FILED, 2014–2025 79 TABLE 17 INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024 81 TABLE 18 ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 82 TABLE 19 US ADJUSTED RECIPROCAL TARIFF RATES 86 TABLE 20 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 91 TABLE 21 SEMAGLUTIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 92 TABLE 22 NORTH AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 92 TABLE 23 EUROPE: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 92 TABLE 24 ASIA PACIFIC: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 93 TABLE 25 LATIN AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 93 TABLE 26 MIDDLE EAST: SEMAGLUTIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 93 TABLE 27 GCC COUNTRIES: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 94 TABLE 28 CALCITONIN MARKET, BY REGION, 2023–2030 (USD MILLION) 94 TABLE 29 NORTH AMERICA: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 30 EUROPE: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 31 ASIA PACIFIC: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 32 LATIN AMERICA: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 96 TABLE 33 MIDDLE EAST: CALCITONIN MARKET, BY REGION, 2023–2030 (USD MILLION) 96 TABLE 34 GCC COUNTRIES: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 96 TABLE 35 LINACLOTIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 97 TABLE 36 NORTH AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 37 EUROPE: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 38 ASIA PACIFIC: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 39 LATIN AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 40 MIDDLE EAST: LINACLOTIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 99 TABLE 41 GCC COUNTRIES: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 99 TABLE 42 TROFINETIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 43 NORTH AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 44 EUROPE: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 45 ASIA PACIFIC: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 46 LATIN AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 47 MIDDLE EAST: TROFINETIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 48 GCC COUNTRIES: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 49 VOCLOSPORIN MARKET, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 50 NORTH AMERICA: VOCLOSPORIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 51 EUROPE: VOCLOSPORIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 52 ASIA PACIFIC: VOCLOSPORIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 53 LATIN AMERICA: VOCLOSPORIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 54 PLECANATIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 104 TABLE 55 NORTH AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 56 EUROPE: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 57 ASIA PACIFIC: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 58 LATIN AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 59 MIDDLE EAST: PLECANATIDE MARKET, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 60 GCC COUNTRIES: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 61 OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 62 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 63 EUROPE: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 64 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 65 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 66 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 67 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 68 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 111 TABLE 69 GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 70 NORTH AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 71 EUROPE: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 72 ASIA PACIFIC: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 73 LATIN AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 74 MIDDLE EAST: GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 75 GCC COUNTRIES: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 76 CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 77 NORTH AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 78 EUROPE: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 79 ASIA PACIFIC: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 80 LATIN AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 81 MIDDLE EAST: CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 82 GCC COUNTRIES: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 83 GC-C AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 84 NORTH AMERICA: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 85 EUROPE: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 86 ASIA PACIFIC: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 87 LATIN AMERICA: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 88 MIDDLE EAST: GC-C AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 89 GCC COUNTRIES: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 90 GPE MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 91 NORTH AMERICA: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 92 EUROPE: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 93 ASIA PACIFIC: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 94 LATIN AMERICA: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 95 MIDDLE EAST: GPE MARKET, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 96 GCC COUNTRIES: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 97 CNI MARKET, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 98 NORTH AMERICA: CNI MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 99 EUROPE: CNI MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 100 ASIA PACIFIC: CNI MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 101 OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 102 NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 103 EUROPE: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 104 ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 105 LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 106 MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 107 GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 108 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 128 TABLE 109 ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 110 NORTH AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 111 EUROPE: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 112 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 113 LATIN AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 114 MIDDLE EAST: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 115 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 116 ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 117 NORTH AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 118 EUROPE: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 119 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 120 LATIN AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 121 MIDDLE EAST: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 122 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 123 ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 124 NORTH AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 125 EUROPE: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 126 ASIA PACIFIC: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 127 LATIN AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 128 MIDDLE EAST: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 129 GCC COUNTRIES: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 130 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 138 TABLE 131 ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 132 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 133 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 134 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 135 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 136 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 137 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 138 ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 139 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 140 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 141 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 142 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 143 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 144 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 145 ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 146 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 147 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 148 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 149 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 150 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 151 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 152 ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 153 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 154 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 155 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 156 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 157 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 158 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 159 ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 160 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 161 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 162 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 163 ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 164 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 165 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 166 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 167 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 168 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 169 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 170 ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 171 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 172 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 173 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 174 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 175 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 176 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 177 ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 160 TABLE 178 ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 179 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 180 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 181 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 182 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 183 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 184 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 185 ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 186 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 187 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 188 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 189 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 190 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 191 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 192 ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023–2030 (USD MILLION) 167 TABLE 193 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 194 EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 195 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 196 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 197 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023–2030 (USD MILLION) 168 TABLE 198 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 199 ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 200 NORTH AMERICA: KEY MACROINDICATORS 172 TABLE 201 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 202 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 174 TABLE 203 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 174 TABLE 204 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 175 TABLE 205 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 175 TABLE 206 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 175 TABLE 207 US: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 176 TABLE 208 US: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 176 TABLE 209 US: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 177 TABLE 210 US: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 177 TABLE 211 US: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 177 TABLE 212 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 178 TABLE 213 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 179 TABLE 214 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 179 TABLE 215 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 180 TABLE 216 CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 180 TABLE 217 EUROPE: KEY MACROINDICATORS 181 TABLE 218 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 219 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 183 TABLE 220 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 184 TABLE 221 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 184 TABLE 222 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 185 TABLE 223 EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 185 TABLE 224 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 186 TABLE 225 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 186 TABLE 226 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 187 TABLE 227 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 187 TABLE 228 GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 187 TABLE 229 UK: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 188 TABLE 230 UK: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 189 TABLE 231 UK: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 189 TABLE 232 UK: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 190 TABLE 233 UK: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 190 TABLE 234 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 191 TABLE 235 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 191 TABLE 236 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 192 TABLE 237 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 192 TABLE 238 FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 192 TABLE 239 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 193 TABLE 240 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 194 TABLE 241 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 194 TABLE 242 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 195 TABLE 243 ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 195 TABLE 244 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 196 TABLE 245 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 196 TABLE 246 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 197 TABLE 247 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 197 TABLE 248 SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 197 TABLE 249 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 198 TABLE 250 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 198 TABLE 251 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 199 TABLE 252 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 199 TABLE 253 NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 199 TABLE 254 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 200 TABLE 255 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 201 TABLE 256 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 201 TABLE 257 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 202 TABLE 258 REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 202 TABLE 259 ASIA PACIFIC: KEY MACROINDICATORS 204 TABLE 260 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 261 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 205 TABLE 262 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 205 TABLE 263 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 206 TABLE 264 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 206 TABLE 265 ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 266 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 207 TABLE 267 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 208 TABLE 268 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 208 TABLE 269 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 209 TABLE 270 CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 209 TABLE 271 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 210 TABLE 272 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 210 TABLE 273 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 211 TABLE 274 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 211 TABLE 275 JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 211 TABLE 276 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 212 TABLE 277 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 213 TABLE 278 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 213 TABLE 279 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 214 TABLE 280 INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 214 TABLE 281 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 215 TABLE 282 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 215 TABLE 283 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 216 TABLE 284 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 216 TABLE 285 AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 216 TABLE 286 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 217 TABLE 287 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 218 TABLE 288 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 218 TABLE 289 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 219 TABLE 290 SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 219 TABLE 291 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 220 TABLE 292 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 220 TABLE 293 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 221 TABLE 294 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 221 TABLE 295 REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 221 TABLE 296 LATIN AMERICA: KEY MACROINDICATORS 222 TABLE 297 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 298 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 223 TABLE 299 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 224 TABLE 300 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 224 TABLE 301 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 225 TABLE 302 LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 225 TABLE 303 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 226 TABLE 304 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 226 TABLE 305 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 227 TABLE 306 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 227 TABLE 307 BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 227 TABLE 308 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 228 TABLE 309 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 229 TABLE 310 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 229 TABLE 311 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 230 TABLE 312 MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 313 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 231 TABLE 314 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 231 TABLE 315 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 232 TABLE 316 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 232 TABLE 317 REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 232 TABLE 318 MIDDLE EAST: KEY MACROINDICATORS 233 TABLE 319 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 234 TABLE 320 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 234 TABLE 321 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 235 TABLE 322 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 235 TABLE 323 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 236 TABLE 324 MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 236 TABLE 325 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 236 TABLE 326 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 237 TABLE 327 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 237 TABLE 328 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 238 TABLE 329 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 238 TABLE 330 GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 331 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 239 TABLE 332 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 240 TABLE 333 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 240 TABLE 334 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 241 TABLE 335 SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 241 TABLE 336 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 242 TABLE 337 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 242 TABLE 338 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 243 TABLE 339 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 243 TABLE 340 UAE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 243 TABLE 341 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 244 TABLE 342 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 244 TABLE 343 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 245 TABLE 344 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 245 TABLE 345 REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 245 TABLE 346 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 246 TABLE 347 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 246 TABLE 348 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 247 TABLE 349 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 247 TABLE 350 REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 351 AFRICA: KEY MACROINDICATORS 249 TABLE 352 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 249 TABLE 353 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION) 250 TABLE 354 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 250 TABLE 355 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 251 TABLE 356 AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION) 251 TABLE 357 OVERVIEW OF STRATEGIES DEPLOYED BY KEY ORAL PROTEIN & PEPTIDE MANUFACTURERS 252 TABLE 358 ORAL PROTEINS & PEPTIDES MARKET: DEGREE OF COMPETITION 255 TABLE 359 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (KEY PLAYERS) 262 TABLE 360 ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE) 262 TABLE 361 ORAL PROTEINS & PEPTIDES MARKET: MOLECULE FOOTPRINT (KEY PLAYERS) 263 TABLE 362 ORAL PROTEINS & PEPTIDES MARKET: FORMULATION FOOTPRINT (KEY PLAYERS) 264 TABLE 363 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (KEY PLAYERS) 264 TABLE 364 ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE) 265 TABLE 365 ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 268 TABLE 366 ORAL PROTEINS & PEPTIDES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 269 TABLE 367 ORAL PROTEINS & PEPTIDES MARKET: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025 271 TABLE 368 ORAL PROTEINS & PEPTIDES MARKET: DEALS, JANUARY 2021–JANUARY 2025 273 TABLE 369 ORAL PROTEINS & PEPTIDES MARKET: EXPANSIONS, JANUARY 2021– JANUARY 2025 274 TABLE 370 ORAL PROTEINS & PEPTIDES MARKET: OTHER DEVELOPMENTS, JANUARY 2021– JANUARY 2025 275 TABLE 371 NOVO NORDISK A/S: COMPANY OVERVIEW 276 TABLE 372 NOVO NORDISK A/S: PRODUCTS OFFERED 277 TABLE 373 NOVO NORDISK A/S: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2025 278 TABLE 374 NOVO NORDISK A/S: DEALS, JANUARY 2021–MARCH 2025 278 TABLE 375 NOVO NORDISK: EXPANSIONS, JANUARY 2021–MARCH 2025 279 TABLE 376 NOVO NORDISK: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025 280 TABLE 377 ABBVIE INC.: COMPANY OVERVIEW 281 TABLE 378 ABBVIE INC.: PRODUCTS OFFERED 282 TABLE 379 ABBVIE INC.: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025 283 TABLE 380 ABBVIE INC.: DEALS, JANUARY 2021–JANUARY 2025 283 TABLE 381 PFIZER INC.: COMPANY OVERVIEW 285 TABLE 382 PFIZER INC.: PRODUCT PIPELINE 286 TABLE 383 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025 287 TABLE 384 PFIZER INC.: DEALS, JANUARY 2021–MARCH 2025 287 TABLE 385 PFIZER INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025 287 TABLE 386 BAUSCH HEALTH COMPANIES: COMPANY OVERVIEW 289 TABLE 387 BAUSCH HEALTH COMPANIES: PRODUCTS OFFERED 290 TABLE 388 BAUSCH HEALTH COMPANIES: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025 291 TABLE 389 CHIESI FARMACEUTICI S.P.A.: COMPANY OVERVIEW 292 TABLE 390 CHIESI FARMACEUTICI S.P.A.: PRODUCTS OFFERED 293 TABLE 391 CHIESI FARMACEUTICI S.P.A.: DEALS, JANUARY 2021–JANUARY 2025 294 TABLE 392 ACADIA PHARMACEUTICALS INC.: COMPANY OVERVIEW 295 TABLE 393 ACADIA PHARMACEUTICALS INC.: PRODUCTS OFFERED 296 TABLE 394 ACADIA PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025 296 TABLE 395 AURINIA PHARMACEUTICALS INC.: COMPANY OVERVIEW 297 TABLE 396 AURINIA PHARMACEUTICALS INC.: PRODUCTS OFFERED 298 TABLE 397 AURINIA PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025 298 TABLE 398 MERCK & CO., INC.: COMPANY OVERVIEW 300 TABLE 399 MERCK & CO., INC.: PRODUCT PIPELINE 301 TABLE 400 MERCK & CO., INC.: DEALS, JANUARY 2021–JANUARY 2025 302 TABLE 401 MERCK & CO., INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 302 TABLE 402 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 303 TABLE 403 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT PIPELINE 304 TABLE 404 JOHNSON & JOHNSON SERVICES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025 305 TABLE 405 SWK HOLDINGS: COMPANY OVERVIEW 306 TABLE 406 SWK HOLDINGS: PRODUCT PIPELINE 307 TABLE 407 SWK HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 307 TABLE 408 R-PHARM JSC: COMPANY OVERVIEW 308 TABLE 409 R-PHARM JSC: PRODUCTS IN PIPELINE 308 TABLE 410 ENTERA BIO: COMPANY OVERVIEW 309 TABLE 411 ENTERA BIO: PRODUCT PIPELINE 309 TABLE 412 ENTERA BIO: DEALS, JANUARY 2021–JANUARY 2025 310 TABLE 413 ENTERA BIO: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 310 TABLE 414 PROXIMA CONCEPTS: COMPANY OVERVIEW 311 TABLE 415 PROXIMA CONCEPTS: PRODUCTS IN PIPELINE 311 _ FIGURE 1 BREAKDOWN OF PRIMARIES: SUPPLY AND DEMAND-SIDE PARTICIPANTS 38 FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024 39 FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2024 40 FIGURE 4 MARKET VALIDATION FROM PRIMARY EXPERTS 41 FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 41 FIGURE 6 CAGR PROJECTIONS: ORAL PROTEINS & PEPTIDES MARKET, 2025–2030 43 FIGURE 7 IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORAL PROTEINS & PEPTIDES MARKET 43 FIGURE 8 DATA TRIANGULATION METHODOLOGY 44 FIGURE 9 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION) 46 FIGURE 10 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY DRUG CLASS, 2025 VS. 2030 (USD MILLION) 47 FIGURE 11 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 47 FIGURE 12 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION, 2025 VS. 2030 (USD MILLION) 48 FIGURE 13 ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 48 FIGURE 14 GEOGRAPHICAL SNAPSHOT OF ORAL PROTEINS & PEPTIDES MARKET 49 FIGURE 15 INCREASING APPROVALS OF ORAL PROTEIN & PEPTIDE DRUGS TO DRIVE MARKET GROWTH 50 FIGURE 16 TABLETS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2024 51 FIGURE 17 DIABETES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 51 FIGURE 18 HOME CARE SETTINGS TO DOMINATE MARKET TILL 2030 52 FIGURE 19 UK TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 52 FIGURE 20 ORAL PROTEINS & PEPTIDES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53 FIGURE 21 ORAL PROTEINS & PEPTIDES MARKET: ECOSYSTEM ANALYSIS 59 FIGURE 22 ORAL PROTEINS & PEPTIDES MARKET: VALUE CHAIN ANALYSIS 62 FIGURE 23 ORAL PROTEINS & PEPTIDES MARKET: SUPPLY CHAIN ANALYSIS 64 FIGURE 24 ORAL PROTEINS & PEPTIDES MARKET: PORTER’S FIVE FORCES ANALYSIS 65 FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF ORAL PROTEINS & PEPTIDES 66 FIGURE 26 KEY BUYING CRITERIA FOR END USERS 67 FIGURE 27 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75 FIGURE 28 PATENT ANALYSIS OF ORAL PROTEINS & PEPTIDE MARKET, JANUARY 2014–JANUARY 2025 80 FIGURE 29 ORAL PROTEINS & PEPTIDES MARKET: INVESTMENT & FUNDING SCENARIO 83 FIGURE 30 NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT 173 FIGURE 31 EUROPE: ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT 182 FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET, 2022–2024 (USD MILLION) 254 FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES (2024) 255 FIGURE 34 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 257 FIGURE 35 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2024 259 FIGURE 36 ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (KEY PLAYERS) 260 FIGURE 37 ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE) 261 FIGURE 38 ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 267 FIGURE 39 EV/EBITDA OF KEY VENDORS 270 FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 270 FIGURE 41 ORAL PROTEINS & PEPTIDES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 271 FIGURE 42 NOVO NORDISK A/S: COMPANY SNAPSHOT (2024) 277 FIGURE 43 ABBVIE INC.: COMPANY SNAPSHOT (2024) 282 FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT (2024) 286 FIGURE 45 BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT (2024) 290 FIGURE 46 CHIESI FARMACEUTICI S.P.A.: COMPANY SNAPSHOT (2024) 293 FIGURE 47 ACADIA PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024) 295 FIGURE 48 AURINIA PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024) 297 FIGURE 49 MERCK & CO., INC.: COMPANY SNAPSHOT (2024) 301 FIGURE 50 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024) 304 FIGURE 51 SWK HOLDINGS: COMPANY SNAPSHOT (2024) 306

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2030

授權報價

報告摘要

同分類最新報告（醫療與生命科學）